Ionis Pharmaceuticals Inc has an analyst consensus of Moderate Buy.
The company has a one year high of $71.50 and a one year low of $30.93. Currently, Ionis Pharmaceuticals Inc has an average volume of 2.12M.
Unlike Leerink Swann`s latest rating, based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IONS in relation to earlier this year. Most recently, in February 2016, Spencer Berthelsen, a a Director at IONS bought 12,500 shares for a total of $74,125.
According to TipRanks.com, Schmidt is a 4-star analyst with an average return of 4.4% and a 52.5% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Five Prime Therapeutics.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery. It operates through two segments: Drug Discovery & Development Operations and Akcea. The Drug Discovery & Development Operations segment provides drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The Akcea segment, which is a subsidiary, focuses on the clinical development of ISIS-APOCIIIRx, ISIS-APO(a)Rx and ISIS-ANGPTL3Rx, as well as more potent follow on drugs from these programs. The company was founded by Stanley T. Crooke in January 1989 and is headquartered in Carlsbad, CA.